ERBB2 and lung adenocarcinoma: By applying HercepTest Dako, other authors obtained a percentage-wise higher prevalence of HER2 overexpression in lung adenocarcinoma in comparison to our results: Awaya et al. 20.9% [22], Yoshizawa et al. 15.2% [20], and Grob et al. 13.9% [23].